Inmunoterapia contra la migraña: uso de erenumab en la vida real
- 23 October 2020
- journal article
- letter
- Published by Elsevier in Revista Clínica Española
- Vol. 221 (9) , 557-559
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central ItalyThe Journal of Headache and Pain, 2020
- The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisalThe Journal of Headache and Pain, 2019
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b studyThe Lancet, 2018
- Erenumab: First Global ApprovalDrugs, 2018
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, 2017